TOP > クイック検索 > 外国特許検索 > CLEC-2 ANTAGONIST, PLATELET AGGREGATION INHIBITOR, ANTITHROMBOTIC AGENT, ANTIMETASTATIC AGENT, ANTIARTHRITIC AGENT, COMPOUND HAVING PORPHYRIN SKELETON, AND METHOD FOR PRODUCING SAME

CLEC-2 ANTAGONIST, PLATELET AGGREGATION INHIBITOR, ANTITHROMBOTIC AGENT, ANTIMETASTATIC AGENT, ANTIARTHRITIC AGENT, COMPOUND HAVING PORPHYRIN SKELETON, AND METHOD FOR PRODUCING SAME UPDATE

外国特許コード F170009129
整理番号 (S2016-0297-N0)
掲載日 2017年7月20日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2017JP000059
国際公開番号 WO 2017119417
国際出願日 平成29年1月4日(2017.1.4)
国際公開日 平成29年7月13日(2017.7.13)
優先権データ
  • 特願2016-000267 (2016.1.4) JP
発明の名称 (英語) CLEC-2 ANTAGONIST, PLATELET AGGREGATION INHIBITOR, ANTITHROMBOTIC AGENT, ANTIMETASTATIC AGENT, ANTIARTHRITIC AGENT, COMPOUND HAVING PORPHYRIN SKELETON, AND METHOD FOR PRODUCING SAME UPDATE
発明の概要(英語) Disclosed is a CLEC-2 antagonist comprising a compound represented by either general formula (1) or general formula (2). (In general formula (1), M represents H2 or one of Group 2 to 12 elements, R1 represents a vinyl group or a 1-hydroxyethyl group, and X represents a Group 1 element.) (In general formula (2), M represents H2 or one of Group 2 to 12 elements, and R2 represents a phenyl group, a sulfophenyl group, a carboxyphenyl group, or a 1-methylpyridinium-4-yl group.)
特許請求の範囲(英語) [claim1]
1. The below-mentioned general formula (1) and the below-mentioned general formula the CLEC-2 competition medicine which features that it consists of the chemical compound where each with (2) is displayed.
(General system (1))
(However, the aforementioned general system (1) in, M H [2] and displays either of the 2-12 family element, R (1) the vinyl basis and 1 - displays either of the hydroxyethyl basis, X displays the 1st family element.)
(General system (2))
(However, the aforementioned general system (2) in, M H [2] and displays either of the 2-12 family element, R (2) phenyl group and sulfonic phenyl group, karubokishihueniru and 1 - mechirupirijiniumu - 4 - displays either of the iru basis.)
[claim2]
2. The aforementioned general system the chemical compound which is displayed with (1), the below-mentioned general formula (1-A) and the below-mentioned general formula (1-B) in the claim 1 which is the chemical compound which is displayed with in each case the CLEC-2 competition medicine of statement.
(General system (1-A))
(However, the aforementioned general system (1-A) in, M H [2], displays either Co, Zn, Ni and Pd, X displays the 1st family element.)
(General system (1-B))
(However, the aforementioned general system (1-B) in, M H [2], displays either Co, Zn and Cu.)
[claim3]
3. The aforementioned general system (1-B) with the chemical compound which is displayed, in the claim 2 which is the chemical compound which is displayed with the below-mentioned structural formula B4 the CLEC-2 competition medicine of statement.
(Structural formula B4)
[claim4]
4. The aforementioned general system the chemical compound which is displayed with (2), from the claim 1 which is the chemical compound which is displayed with the below-mentioned structural formula C1 in either of 3 the CLEC-2 competition medicine of statement.
(Structural formula C1)
[claim5]
5. The blood platelet cohesion inhibiter which features that from claim 1 it consists of the CLEC-2 competition medicine of statement in either of 4.
[claim6]
6. The anti- thrombus medicine which features that from claim 1 it consists of the CLEC-2 competition medicine of statement in either of 4.
[claim7]
7. The anti- transfer medicine which features that from claim 1 it consists of the CLEC-2 competition medicine of statement in either of 4.
[claim8]
8. The anti- arthritis medicine which features that from claim 1 it consists of the CLEC-2 competition medicine of statement in either of 4.
[claim9]
9. The below-mentioned general formula (1-A) and the below-mentioned general formula (1-B) the chemical compound which features that it is displayed with in each case.
(General system (1-A))
(However, the aforementioned general system (1-A) in, M displays either Co, Zn, Ni and Pd, X displays the 1st family element.)
(General system (1-B))
(However, the aforementioned general system (1-B) in, M displays either Co, Zn and Cu.)
[claim10]
10. The salt and metal acetate of the protoporphyrin, when either dimethyl sulfoxide and acetic acid, under existing of the water, 1 hour -30 hours reacting with the 70.deg.C-95.deg.C, the below-mentioned general formula (1-A) with production method of the chemical compound which features that the process which obtains the chemical compound which is displayed is included.
(General system (1-A))
(However, the aforementioned general system (1-A) in, M displays either Co, Zn, Ni and Pd, X displays the 1st family element.)
[claim11]
11. Under each existing of methanol and acetic acid, 5 hour -30 hours reacting the hematoporphyrin and metal acetate, with the 15.deg.C-30.deg.C, the below-mentioned general formula (1-B) with production method of the chemical compound which features that the process which obtains the chemical compound which is displayed is included.
(General system (1-B))
(However, the aforementioned general system (1-B) in, M displays either Co, Zn and Cu.)
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • UNIVERSITY OF YAMANASHI
  • 発明者(英語)
  • INOUE KATSUE
  • OSADA MAKOTO
  • KOJIMA SOICHI
  • SAITO TAMIO
  • SASAKI TOMOYUKI
  • SHIRAI TOSHIAKI
  • SHINMORI HIDEYUKI
  • MOCHIZUKI CHIHIRO
国際特許分類(IPC)
指定国 (WO2017119417)
National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
上記の特許・技術に関心のある方は、下記問合せ先にご相談下さい。

PAGE TOP

close
close
close
close
close
close